ALLR · Allarity Therapeutics, Inc. · Metrics
Market Cap
$14.07M
Shares
15.91M
Volume · Oct 21
84.46K
Avg daily vol (3M)
102.87K
ALLR metrics
67 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$0.88
Market cap
$14.07M
Price action
20 metricsPrice change (1W)
+0.7%
Price change (30D)
-25.1%
Price change (3M)
-28.2%
Price change (6M)
-36.5%
Price change (YTD)
-18.9%
Price change (1Y)
-42.0%
Trailing year
Price change (5Y)
—
52-week high
$1.77
52-week low
$0.81
Change from 52-week high
-50.5%
Change from 52-week low
+8.1%
Annualized volatility
77.0%
Annualized volatility (3M)
64.2%
Beta
1.5
RSI (14D)
34.1
Price vs SMA 50
-25.5%
Price vs SMA 200
-28.7%
Avg volume (3M)
102,874
Relative volume
1.1
Average dollar volume
$118,218
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
15.91M
Valuation
12 metricsP / E (TTM)
0.0
Trailing earnings · reciprocal yield 22,793,354.6%
PEG ratio
—
EV / revenue
55.8×
reciprocal yield 1.8%
EV / EBITDA
—
EV / EBIT
—
P / sales
40.4×
reciprocal yield 2.5%
P / book
3.9
reciprocal yield 25.4%
FCF yield
—
TTM · current market cap
Buyback yield
6.4%
P / FCF
—
P / operating cash flow
—
Earnings yield
-88.4%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
6.4%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
-3,939.1%
Trailing 12 months
Net margin
-3,509.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$10.79M
Net income (TTM)
−$12.33M
Trailing 12 months
Diluted EPS (TTM)
$199,624.20
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$345,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+80,341.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-348.8%
Return on assets
-38.4%
Debt / equity
6.3
Current ratio
1.1
EBITDA (TTM)
−$26.77M
Free cash flow (TTM)
—
Quick ratio
1.1
Interest coverage
-10.1
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$5.30M
Latest balance sheet
Cash & equivalents
$16.98M
Total assets
$32.12M
Total debt
$22.29M
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$13.71M
Capital expenditures (TTM)
$72,000
R&D (TTM)
$5.52M
SG&A (TTM)
—
Stock compensation (TTM)
$527,000
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
20
13F filer change QoQ
+6
Institutional ownership
8.1%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
4.3%
Private-fund adviser ownership
3.5%
Active holders' share change QoQ
+115.2%
Holder tenure
3.1
Price vs estimated holder cost
-1.3%
Ownership (registered funds)
1 metricsIndex-fund ownership
1.9%
Short interest
3 metricsShort interest
0.7%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
31 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—